Results 191 to 200 of about 78,686 (205)

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Lancet, The, 2012
Axel Hauschild, Jean-Jacques Grob, Ralf Gutzmer   +2 more
exaly  

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

New England Journal of Medicine, 2012
Keith T Flaherty, Caroline Robert, Claus Garbe   +2 more
exaly  

Commentary: BRAF inhibitors for metastatic melanoma

British Journal of Dermatology, 2013
openaire   +2 more sources

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

Cancer Discovery, 2013
Rumin Zhang, Alan Hruza, Ulrike Philippar   +2 more
exaly  

Vemurafenib: the first drug approved for BRAF-mutant cancer

Nature Reviews Drug Discovery, 2012
exaly  

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Cancer Discovery, 2014
Hubing Shi, Willy Hugo, Gatien Moriceau
exaly  

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Nature Reviews Clinical Oncology
Ziyu Chen, David B Solit
exaly  

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

Molecular Cancer, 2014
David Foulad, Thomas Glen Graeber, Roger S Lo   +2 more
exaly  

[BRAF inhibitor and MEK inhibitor].

Gan to kagaku ryoho. Cancer & chemotherapy, 2015
openaire   +1 more source

BRAF and MEK Inhibitors

2013
openaire   +1 more source